Unit of Surgery1 (Endocrine Surgery), San Martino University Hospital, Genoa, Italy -
Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy -
Minerva Endocrinol (Torino). 2024 Jun;49(2):132-140. doi: 10.23736/S2724-6507.21.03526-0. Epub 2021 Oct 20.
Severe and/or symptomatic hypocalcemia due to hypoparathyroidism is the main contraindication for discharge in patients who have undergone thyroid surgery. Hypomagnesemia may contribute to the onset of hypoparathyroidism and is frequently observed after thyroid surgery in hypocalcemic patients. The impact of prophylactic and postoperative Magnesium supplementation on postoperative hypocalcemia and hypomagnesemia was prospectively evaluated by comparing patients undergoing prophylactic supplementation to a control group of patients who had only received magnesium after evidence of postoperative hypomagnesemia.
One hundred and twenty patients who underwent a total thyroidectomy participated in the study. Seventy-three patients were included in the study group, 47 in the control group. Prior to surgery, patients in the study group were given magnesium orally for 5 days; postoperatively, calcium and magnesium was administered to all patients who displayed hypocalcemia and hypomagnesemia.
Postoperative biochemical hypocalcemia (serum calcium <8.5 mg/dL, regardless of its clinical severity) was found in 60 patients (50%) on D1 and in 58 patients (48.4%) on D2. Among hypocalcemic patients, hypomagnesemia was recorded in 29 at D1 (48%), and in 46 at D2 (79%). A significant positive correlation was found between magnesium, calcium, and parathyroid hormone in the first two postoperative days, while a significant inverse correlation occurred for these same parameters and length of hospital stay (P<0.001). One hundred and five patients (87.5%) were discharged as expected on the second postoperative day (65 in the study group, 40 in the control group, P=0.724), whereas 15 patients (12.5%) required prolonged hospitalization (eight in the study group, seven in the control group, P=0.721). The Study group only showed significantly higher magnesium levels on the first postoperative day (P=0.03).
Although magnesium and calcium levels showed the same trend after thyroidectomy, neither Magnesium prophylaxis nor Magnesium treatment influenced the clinical course of postoperative hypocalcemia.
甲状旁腺功能减退导致的严重和/或有症状的低钙血症是甲状腺手术后患者出院的主要禁忌。低镁血症可能导致甲状旁腺功能减退的发生,并在低钙血症患者甲状腺手术后经常观察到。通过比较预防性补充镁的患者和仅在术后低镁血症证据后接受镁治疗的对照组患者,前瞻性评估预防性和术后补充镁对术后低钙血症和低镁血症的影响。
120 例接受全甲状腺切除术的患者参与了这项研究。73 例患者被纳入研究组,47 例患者被纳入对照组。术前,研究组患者口服镁 5 天;术后,所有出现低钙血症和低镁血症的患者均给予钙和镁。
术后第 1 天,60 例(50%)患者出现生化性低钙血症(血清钙<8.5mg/dL,无论其临床严重程度如何),第 2 天 58 例(48.4%)患者出现低钙血症。在低钙血症患者中,第 1 天记录到 29 例(48%)低镁血症,第 2 天记录到 46 例(79%)低镁血症。在术后前两天,镁、钙和甲状旁腺激素之间存在显著的正相关,而这些相同的参数与住院时间之间存在显著的负相关(P<0.001)。第 2 天,105 例(87.5%)患者按预期出院(研究组 65 例,对照组 40 例,P=0.724),15 例(12.5%)患者需要延长住院时间(研究组 8 例,对照组 7 例,P=0.721)。研究组仅在术后第 1 天显示出显著较高的镁水平(P=0.03)。
尽管甲状腺切除术后镁和钙水平呈相同趋势,但镁的预防性或治疗性补充都不影响术后低钙血症的临床病程。